Immunocore's KIMMTRAK franchise is driving accelerating revenue growth (18.3% YoY in 2026Q2) with gross margins above 99%, and operating losses have narrowed dramatically from -$14.9M in 2025Q2 to -$3.0M in 2026Q2, signaling a path to break-even.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | -$0.28-114.6% vs -$0.13 | $102M-32.8% vs $152M |
Q3 2026 Aug 6, 2026 | -$0.02-100.0% vs -$0.01 | $116M-22.1% vs $149M |
Q2 2026 May 6, 2026 | $0.25+196.2% vs -$0.26 | $145M-0.3% vs $145M |
Q1 2026 Feb 25, 2026 | -$0.60-114.3% vs -$0.28 | $140M-3.1% vs $144M |
In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes Preclinical data supporting unique mechanism of action recently published in Science Advances (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that the first patient with type 1 diabetes (T1D) has been dosed in the Phase 1 trial (NCT07493122) of IMC-S118AI1. IMC-S118AI, the Company's first candidate for autoimmune diseases, is a novel bispecific molecule designed to down-modulate the immune system in a tissue-specific manner to protect beta cells under T cell attack in T1D.
Benchmark IMCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Immunocore Holdings plc (IMCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.99 | $1.58B | -65.66 | 20% | -6.05% | -6.03% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — |
Immunocore Holdings plc (IMCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Immunocore Holdings plc (IMCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 27, 2026·SEC
May 6, 2026·SEC
Get notified when IMCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Immunocore Holdings plc (IMCR) stock FAQ — growth, dividends, profitability & financials explained
Immunocore Holdings plc (IMCR) reported $402.3M in revenue over the trailing twelve months. Revenue was $297.6M in fiscal year 2025. That is 8914% more than the $3.3M of fiscal year 2013.
Immunocore Holdings plc (IMCR) grew revenue by 6.0% over the trailing twelve months, compared with the twelve months before.
No. Immunocore Holdings plc (IMCR) reported a net loss of $24.3M over the trailing twelve months.
Immunocore Holdings plc (IMCR) had a return on equity (ROE) of -6.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Immunocore Holdings plc (IMCR) had negative free cash flow of $18.2M over the trailing twelve months.
